Healio Covers Research on the Syn-One Test’s Role for People with REM Sleep Behavior Disorder
A recent article in Healio highlighted research showing how CND Life Sciences’ Syn-One Test® detects a key neurodegenerative biomarker in idiopathic REM sleep behavior disorder (iRBD) – and what this might mean for patient care.
The article highlighted baseline findings from a National Institutes of Health (NIH) funded study showing that the skin biopsy procedure detected phosphorylated alpha-synuclein (P-SYN) in 75% of study participants.
“While REM sleep behavior disorder can have multiple causes—including narcolepsy, medications or other sleep disorders—the majority of individuals with idiopathic RBD are believed to be in the prodromal stage of developing synucleinopathies such as Parkinson’s disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA),” Todd D. Levine, MD, chief medical officer of CND Life Sciences.
The ability to detect P-SYN with the relative ease and convenience of the Syn-One Test can help guide clinicians’ treatment decisions.
“The Syn-One Test may be able to detect this problem a decade or more before clinical symptoms of a synucleinopathy emerge and facilitate lifestyle changes, clinical monitoring, and even inclusion in disease prevention trials for patients who wish to be more proactive,” Levine said.
The 24-month, longitudinal, prospective cohort study included 80 participants (mean age, 67.8±8.9 years) with confirmed iRBD either through the REM Sleep Disorder Screening Questionnaire (RBDSQ; n = 47) or by polysomnogram (PSG; n = 33) enrolled at 11 sites across the US.
